« Previous Next » Nuclear Medicine and Biology
Volume 37, Issue 4 , Pages 421-426 , May 2010

[¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 — metabolic considerations

Daniela Haeusler
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
- The authors contributed equally.
Lukas Nics
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
- Department of Nutritional Sciences, University of Vienna, A-1090 Vienna, Austria
- The authors contributed equally.
Leonhard-Key Mien
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
Johanna Ungersboeck
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
- Department of Inorganic Chemistry, University of Vienna, A-1090 Vienna, Austria
Rupert R. Lanzenberger
- Department of Psychiatry and Psychotherapy, Medical University of Vienna, A-1090 Vienna, Austria
Karem Shanab
- Department of Drug and Natural Product Synthesis, University of Vienna, A-1090 Vienna, Austria
Karoline M. Sindelar
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
Helmut Viernstein
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
Karl-Heinz Wagner
- Department of Nutritional Sciences, University of Vienna, A-1090 Vienna, Austria
Robert Dudczak
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
Kurt Kletter
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
Wolfgang Wadsak
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
- Department of Inorganic Chemistry, University of Vienna, A-1090 Vienna, Austria
Markus Mitterhauser
- Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
- Hospital Pharmacy of the General Hospital of Vienna, A-1090 Vienna, Austria
- Corresponding author. Department of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel.: +43 1 40400 1557; fax: +43 1 40400 1559.

Received 17 September 2009 ,Revised 17 December 2009 ,Accepted 1 January 2010.

References

Baraldi PG, Cacciari B, Romagnoli R, Merighi S, Varani K, Borea PA, et al. A₃ adenosine receptor ligands: history and perspectives. Med Res Rev. 2000;20:103–128
- MEDLINE
- CrossRef
Fishman P, Bar-Yehuda S, Madi L, Cohn I. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs. 2002;13:437–443
- MEDLINE
- CrossRef
Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res. 2004;10:4472–4479
- MEDLINE
- CrossRef
Li AH, Moro S, Forsyth N, Melman N, Ji XD, Jacobson KA. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1999;42:706–721
- MEDLINE
- CrossRef
Wadsak W, Mien LK, Shanab K, Weber K, Schmidt B, Sindelar KM, et al. Radiosynthesis of the adenosine A₃ receptor ligand 5-(2-[¹⁸F]fluoroethyl)2,4-diethyl-3-(ehtylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY). Radiochim. Acta. 2008;96:119–124
Wadsak W, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar K, et al. Preparation and first evaluation of [¹⁸F]FE@SUPPY: a new PET tracer for the adenosine A₃ receptor. Nucl Med Biol. 2008;35:61–66
Kiesewetter DO, Lang L, Ma Y, Bhattacharjee AK, Gao ZG, Joshi BV, et al. Synthesis and characterization of [⁷⁶Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography. Nucl Med Biol. 2009;36:3–10
Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol. 1998;38:257–288
- MEDLINE
- CrossRef
Haeusler D, Mitterhauser M, Mien LK, Shanab K, Lanzenberger RR, Schirmer E, et al. Radiosynthesis of a novel potential adenosine A₃ receptor ligand 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl) sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY:2). Radiochim Acta. 2009;97:753–758
Mitterhauser M, Haeusler D, Mien LK, Ungersboeck J, Nics L, Lanzenberger RR, et al. Automatisation and first evaluation of [¹⁸F]FE@SUPPY:2, an alternative PET-Tracer for the adenosine A₃ receptor: a comparison with [¹⁸F]FE@SUPPY. The Open Nuclear Medicine Journal. 2009;1:15–23
Azéma L, Lherbet C, Baudoin C, Blonski C. Cell permeation of a Trypanosoma brucei aldolase inhibitor: evaluation of different enzyme-labile phosphate protecting groups. Bioorg Med Chem Lett. 2006;16:3440–3443
- MEDLINE
- CrossRef
Shanab K, Wadsak W, Mien LK, Mitterhauser M, Holzer W, Polster V, et al. Synthesis of in vivo metabolites of the new adenosine A3 receptor PET-radiotracer[¹⁸F]FE@SUPPY. Heterocycles. 2008;75:339–356
Shanab K. Synthesis of precursors of adenosine A₃ receptor PET-tracers: in the nuclear medicine's service. Synthese von Precursoren von A3-Adenosin-Rezeptor PET-Tracern: Im Dienste der Nuklearmedizin, Wien: Vdm Verlag; 2008;
Stoops JK, Hamilton SE, Zerner B. Carboxylesterases (EC 3.1.1). A comparison of some kinetic properties of horse, sheep, chicken, pig and ox liver carboxylesterases. Can J Biochem. 1975;53:865–873